Last checked at 9 Jul 2018 14:37
hVIVO plc
("hVIVO" or the "Company")
Directorate change
London, UK, 9 July 2018: hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development services business, announces that, further to the statement issued on 19 April 2018 in which it was announced that Kym Denny had stepped down as CEO, Kym Denny is no longer a Director of the Company and of its subsidiaries as of today's date.
- Ends -
For further information please contact:
hVIVO plc | +44 207 756 1300 |
Trevor Phillips (Executive Chairman) | |
Fleur Wood (Director, Investor Relations) | |
Numis Securities Limited | +44 207 260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) | |
James Black / Michael Burke (Corporate Broking) | |
FTI Consulting | |
Simon Conway / Victoria Foster Mitchell | +44 203 727 1000 |
About hVIVO plc
hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.